Publication — IRIC

Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting.

Current strategies for risk stratification of patients with acute myeloid leukemia assign approximately 40% of patients to the intermediate-risk group, where uncertainty about optimal therapy still persists.

Date de publication
7 août 2019
Chercheurs
Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hébert J
Référence PubMed
Appl Health Econ Health Policy 2019
ID PubMed
31392669
Affiliation
Purple Squirrel Economics, New York, NY, USA. gabrielt.ecn@gmail.com.